IMMP
Closed
Immutep Ltd Adr
1.65
+0.01 (+0.61%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.64
Day's Range: 1.63 - 1.71
Send
sign up or login to leave a comment!
When Written:
1.64
Immutep Ltd is a biotechnology company that develops immunotherapy treatments for cancer and autoimmune diseases. The company's lead product candidate is eftilagimod alpha, which is being developed for the treatment of multiple types of cancer. Immutep also has a number of other product candidates in development, including IMP761 for autoimmune diseases and IMP701 for cancer. The company is headquartered in Sydney, Australia, and has operations in Europe and the United States. Immutep's American Depositary Receipts (ADRs) trade on the NASDAQ under the ticker symbol IMMP.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








